Aggressive Prostate Cancer

Treating Gleason 9–10 Prostate Cancer 

According to Anthony V. D’Amico, MD, Ph.D., who is chief of the Division of Genitourinary Radiation Oncology and an institute physician at Dana-Farber Cancer Institute at Brigham and Women’s Hospital in Boston, “It makes logical sense that in these very aggressive prostate cancers, you need a multi-modality approach.”

Two Studies Released At ASCO Demonstrate A Survival Advantage For Men Who Take Early Zytiga With ADT

Two game changing trials demonstrated that the early use of Zytiga along with hormone therapy (ADT) can provide a significant survival advantage for men with aggressive, hormone naive prostate cancer.  The data is very clear for men with metastatic disease, but there remains some controversy if this holds up for men who are not metastatic.